Literature DB >> 21042168

Why do physicians prescribe stress ulcer prophylaxis to general medicine patients?

Syed Hussain1, Mihaela Stefan, Paul Visintainer, Michael Rothberg.   

Abstract

BACKGROUND: Little is known about why physicians prescribe inappropriate stress ulcer prophylaxis (SUP) among nonintensive care unit (ICU) hospitalized patients without supporting evidence. This study seeks to understand which factors influence physician prescribing behavior regarding SUP.
DESIGN: We designed a cross sectional web-based survey to assess physicians' knowledge, beliefs, and behavior surrounding the prescribing of SUP for non-ICU patients. The survey was emailed to internal medicine residents and hospitalists at a university-affiliated tertiary care hospital. Clinically relevant bivariable associations were examined in logistic regression to determine whether these associations remained after adjustment for potential confounding factors.
RESULTS: Sixty-nine percent of physicians reported prescribing SUP to ≥25% of patients. In multivariable analyses, the following factors were associated with higher level of prescribing (≥25%) of SUP: fear of gastrointestinal bleeding (OR = 2.7, 95% CI 1.07, 7.28) and of the legal repercussions of not prescribing SUP (OR = 3.02, 95% CI 1.07, 8.56), whereas knowledge of SUP indications (OR = 0.39, 95% CI 0.20, 0.74) and concern about side effects (OR = 0.24, 95% CI 0.09, 0.61) were associated with low prescribing behavior. Level of training was not associated with prescribing rate. Less than half of respondents were able to identify a single side effect of proton pump inhibitor therapy.
CONCLUSION: Fear of legal repercussions and ignorance of the side effects of acid suppressive therapy were strongly associated with inappropriate prescribing of SUP. Educating physicians about the adverse effects of acid suppression therapy and about existing national guidelines might reduce inappropriate prescribing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21042168     DOI: 10.1097/SMJ.0b013e3181f6539d

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  7 in total

1.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

2.  Appropriateness and Associated Factors of Stress Ulcer Prophylaxis for Surgical Inpatients of Orthopedics Department in a Tertiary Hospital: A Cross-Sectional Study.

Authors:  Haiyan Li; Ning Li; Xiaoni Jia; Yuyao Zhai; Xiaorong Xue; Yi Qiao
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 3.  Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences.

Authors:  Jeffrey F Barletta; David A Sclar
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

4.  Prescribing errors among adult patients in a large tertiary care system in Saudi Arabia.

Authors:  Maryam Ali Alharaibi; Abdullah A Alhifany; Yousif A Asiri; Monira M Alwhaibi; Sheraz Ali; Parameaswari P Jaganathan; Tariq M Alhawassi
Journal:  Ann Saudi Med       Date:  2021-06-01       Impact factor: 1.526

5.  Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review.

Authors:  Sooyoung Shin
Journal:  Ther Clin Risk Manag       Date:  2015-05-24       Impact factor: 2.423

6.  Attitude and Knowledge of Indian Emergency Care Residents towards Use of Proton Pump Inhibitors.

Authors:  Biswa Mohan Padhy; Hemant Singh Bhadauria; Yogendra Kumar Gupta
Journal:  Int Sch Res Notices       Date:  2014-11-19

7.  Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.

Authors:  Hongli Luo; Qingze Fan; Shunlin Xiao; Kun Chen
Journal:  BMC Health Serv Res       Date:  2018-07-11       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.